My Info

CancerCure Technology Ltd
Pharmaceutical/Biotech
Chairman/Owner/CEO/Partner

Intellectual Property Listings

Cancer Treatment Technology
The system facilitates quality assurance means by MR monitoring of drug accumulation and subsequent drug release, in real time. Selective drug release and/or hyperthermia (increased temperature) are achieved by ultrasound well defined to the tumor region.

Projects

CancerCure Technology

CancerCure Technology Ltd. (CCT) is a company working on Magnetic Resonance (MR) guided cancer treatment systems and selectively induced drug release for significantly improved therapeutic index (survival). The technology represents real time monitoring, novel combinations and optimization of current treatment regimes. Lead time to market – 2.5 years. The technology is patented (approved). Total market size USD 45 bill. (2004).

Oncological objectives

  • Aiming for cure for those 20 % who die from local complications.
  • Significant increase in therapeutic index (5-year survival) for those 80 % who die from metastases.

Cooperating bodies

CCT has a development agreement with Rikshospitalet (The National Hospital of Norway), close ties to The Radium Hospital and The Norwegian University of Science and Technology. The Company has received a grant (NOK 3.5 mill.) from "Innovation Norway" and is approved for "Skattefunn" (20 % refund of R&D expenditures) by the Research Council of Norway.

Scientific Achievements

Papers

Myhr G. MR guided cancer treatment system for an elevated therapeutic index – a macroscopic approach. Med Hypotheses (2007a), doi:10.1016/j.mehy.2007.06.025.

Myhr G. Multimodal ultrasound mediated drug release model in local cancer therapy. Med Hypotheses (2007b), doi10.1016/j.mehy.2007.03.006

Myhr G, Moan J. Synergistic effects of chemotherapy and ultrasound treatment. Cancer Letters 2006;232; 206-213.

Patents

MR guided cancer treatment system. Patent No.: GB 07116662.7
Priority date: June 15, 2007. UK/USA.

Therapeutic Ultrasound System. Patent No.: WO 2006/129099
Priority date: June 2, 2005 (UK). Approved IPER by the PCT.

Therapeutic probe, method and system. US Patent No.: 7,220,258
Granted: USA, February 2007.

Apparatus for selective cell destruction within a living organism. Patent No.: PCT/NO2001/000349. Granted: Norway, April 2002, EPO (DE, ES, FR, UK, IT), July 2005. Pending USA.